Vera Therapeutics, Inc. - Class A Common Stock (VERA)

The new credit facility features a lower interest rate, increasing capital availability and financial flexibility, the company stated.

Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Vera Therapeutics shares are trading lower by 4.7% Monday afternoon. The company announced an exclusive license agreement with Stanford University for VT-109.

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Vera Therapeutics' share price surged over 65% during the pre-market trading session after the company released ORIGIN Phase 3 trial data.

Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.

Vera Therapeutics completes enrollment in Phase 3 atacicept trial for IgAN, with interim efficacy results expected this quarter to support 2025 FDA filing.

Vera Therapeutics announces ORIGIN Phase 2b trial data on atacicept, showing sustained IgAN improvement and kidney function stability over 96 weeks.

The company is working on a treatment for IgA nephropathy, a condition that affects how well the kidneys work.

VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

U.S. stock market ends 5-week positive streak due to slowing economic momentum, while Nvidia's valuation soars and home prices hit record highs.

NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking.